Lobe Sciences

Lobe Sciences will participate in the Clusterbusters 20th Annual U.S. Patient Conference (Sept 11-14, 2025) to present research on L-130, Conjugated Psilocin™, a potential treatment for chronic cluster headaches. The company recently secured $6 million in funding, with a potential $20 million more, to complete FDA submission for L-130. Lobe aims to connect with patients, form an advocacy team, and gather input for clinical trial design, leveraging patient experiences provided by Clusterbusters, a supporting advocacy group.

Lobe Sciences announced the validation of its European Unitary Patent EP4117446 across 17 EU member states, covering its proprietary DHA-based composition for Sickle Cell Disease (SCD). This patent protects Altemia®, an innovative medical food designed to improve red blood cell integrity and address fatty acid deficiencies in SCD patients. The validation significantly strengthens Lobe’s intellectual property in crucial European territories, advancing its commercialization roadmap for Altemia®.